Deutsche Bank AG lifted its holdings in Sanofi SA (NYSE:SNY) by 369.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,462,947 shares of the company’s stock after buying an additional 1,151,455 shares during the quarter. Deutsche Bank AG owned approximately 0.06% of Sanofi worth $62,903,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Baldwin Brothers Inc. MA lifted its position in shares of Sanofi by 106.7% in the 4th quarter. Baldwin Brothers Inc. MA now owns 11,121 shares of the company’s stock worth $478,000 after buying an additional 5,742 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Sanofi by 7.0% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 1,558,400 shares of the company’s stock worth $77,593,000 after buying an additional 101,718 shares during the last quarter. Beacon Financial Group lifted its position in shares of Sanofi by 12.5% in the 4th quarter. Beacon Financial Group now owns 105,488 shares of the company’s stock worth $4,536,000 after buying an additional 11,761 shares during the last quarter. Epstein & White Financial LLC bought a new position in shares of Sanofi in the 4th quarter worth about $298,000. Finally, Argent Trust Co lifted its position in shares of Sanofi by 32.0% in the 3rd quarter. Argent Trust Co now owns 10,841 shares of the company’s stock worth $540,000 after buying an additional 2,629 shares during the last quarter. Institutional investors own 8.94% of the company’s stock.
A number of research analysts have recently issued reports on SNY shares. Morgan Stanley downgraded shares of Sanofi from an “overweight” rating to an “underweight” rating in a research report on Friday, December 1st. Nord/LB restated a “neutral” rating on shares of Sanofi in a research report on Wednesday, December 27th. Barclays downgraded shares of Sanofi from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, January 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, December 14th. Finally, Cowen set a $48.00 price objective on shares of Sanofi and gave the company a “hold” rating in a research report on Monday, December 18th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $49.33.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.07). The firm had revenue of $8.69 billion during the quarter, compared to the consensus estimate of $8.65 billion. Sanofi had a net margin of 23.25% and a return on equity of 24.30%. The company’s revenue for the quarter was down 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.25 earnings per share. equities analysts predict that Sanofi SA will post 3.36 earnings per share for the current year.
The company also recently disclosed an annual dividend, which will be paid on Monday, June 4th. Investors of record on Thursday, May 10th will be given a $1.8609 dividend. The ex-dividend date is Wednesday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.58. This represents a yield of 4.72%. Sanofi’s dividend payout ratio (DPR) is currently 30.14%.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.